Loading data for NGEN — first visit, this takes a few seconds.
NervGen Pharma Corp. (NGEN)
NasdaqCM: NGEN
· 即時價格 · USD
2.33
+0.01 (0.43%)
收盤價： Sep 08, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
NervGen Pharma Corp.（NGEN）股價、分析與資料
0.43% (1D)
| 買價 | 1.65 |
| 市值 | 235M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -62M |
| 0.73 | |
| -0.57 | |
| n/a | |
| -6.42 | |
| P/B (ttm) | 18.71 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 23, 2026 |
| 賣價 | 2.94 |
| 成交量 | 920,546 |
| 20 日平均成交量 | 685,031 |
| 開盤價 | 2.29 |
| 前收盤價 | 2.32 |
| 當日區間 | 2.27 - 2.39 |
| 52 週範圍 | 1.58 - 6.30 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical mo...
完整的公司簡介財報驚奇
NervGen Pharma 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.23 低於預期 -0.16, 年增 -475.00% 下滑.
